Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Bone Marrow Transplant. 2016 May 23;51(10):1342–1349. doi: 10.1038/bmt.2016.142

Table 3. Outcome-specific analyses of high-risk amino acid substitution position and type in the validation cohort.

Hazard Ratio 95% Confidence Interval p-value
Overall Survival1 No AASPT (n=575) vs. 8/8 1.38 1.22-1.57 <0.0001
At least 1 AASPT (n=170) vs. 8/8 1.55 1.26-1.91 <0.0001
At least 1 AASPT vs. no AASPT 1.12 0.89-1.41 0.33
Disease-Free Survival2 No AASPT (n=638) vs. 8/8 1.33 1.18-1.49 <0.0001
At least 1 AASPT (n=106) vs. 8/8 1.50 1.17-1.93 0.0012
At least 1 AASPT vs. no AASPT 1.13 0.87-1.47 0.35
Treatment-Related Mortality3 No AASPT (n=539) vs. 8/8 1.61 1.37-1.91 <0.0001
At least 1 AASPT (n=205) vs. 8/8 1.75 1.38-2.22 <0.0001
At least 1 AASPT vs. no AASPT 1.09 0.83-1.42 0.54
Grades III-IV Acute GvHD4 No AASPT (n=336) vs. 8/8 1.74 1.36-2.22 <0.0001
At least 1 AASPT (n=172) vs. 8/8 1.52 1.08-2.14 0.015
At least 1 AASPT vs. no AASPT 0.88 0.60-1.29 0.50
1

Adjusted for patient age, CMV match, conditioning, donor age, disease status, KPS; stratified by graft type.

2

Adjusted for patient age, CMV match, donor age, disease status, KPS, year of transplantation; stratified by graft type and disease type.

3

Adjusted for patient age, donor age, disease, disease status, KPS; stratified by graft type

4

Adjusted for patient sex; stratified by graft type.

Abbreviations: AAS, high-risk AASPT defined by the training dataset; GvHD, graft-versus-host disease; CMV, cytomegalovirus